Skip to content

Choroidal Response to Novel Spectacle Lens to Control Myopia Progression

A Sub-Study to Assess the Choroidal Response to Novel Spectacle Lens to Control Myopia Progression (CHERRY)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03818880
Acronym
CHERRY
Enrollment
10
Registered
2019-01-28
Start date
2018-12-18
Completion date
2026-12-31
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia, Progressive

Keywords

Myopia, Myopia control

Brief summary

Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.

Detailed description

Diurnal variations in the thickness of the choroid have been reported in the literature , and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression. SightGlass Vision, Inc is conducting a multi-site, randomized, controlled, interventional study to confirm the efficacy and safety of spectacle lenses designed to inhibit the progression of myopia by reducing image contrast in peripheral vision. CORE is participating as a clinical site in this three year study which aims to compare changes in ocular length and cycloplegic auto-refraction in children randomised to wear one of either two test or one control spectacle lens designs; the CPRO-1802-001 (Cypress\_SG) study. The sponsor is interested in conducting choroidal thickness measurements only at CORE's site by inviting those participants who have already been found eligible for the CPRO-1802-001 study to participate in this parallel study.

Interventions

Spectacle lens to control progression of myopia

Sponsors

SightGlass Vision, Inc.
Lead SponsorINDUSTRY
University of Waterloo
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 10 Years
Healthy volunteers
Yes

Inclusion criteria

* Participating in the CPRO-1802-001 (Cypress\_SG) study at CORE * Read and signed an Assent and their parent/guardian has signed an information consent letter

Exclusion criteria

* Transient health condition which may affect the eye(s) (e.g. a common cold, active allergies, fatigue, etc;)

Design outcomes

Primary

MeasureTime frameDescription
Choroidal thickness3 yearsMeasurement of choroidal thickness by Triton optical coherence tomographer (OCT), including post-imaging analysis

Secondary

MeasureTime frameDescription
Visual field3 yearsAssessment of visual field to determine if changes in peripheral visual function by Humphrey Visual Field Analyzer

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORLyndon Jones, PhD, FCOptom

Centre for Ocular Research & Education, Canada

STUDY_DIRECTORJill Woods, BSc, MCOptom

Centre for Ocular Research & Education, Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026